Chris Deluzio

Chris Deluzio serves as the Executive Vice President of Enterprise Operations at NewAmsterdam Pharma since September 2023, focusing on developing operational infrastructure. Prior to this role, Chris held prominent positions at Biohaven Pharmaceuticals from June 2019 to March 2023, including SVP of Biohaven Enterprise Operations and as the commercial integration lead following Biohaven's acquisition by Pfizer in October 2022. Chris's extensive experience also includes leadership roles at Takeda, AstraZeneca, Boehringer Ingelheim, Sunovion Pharmaceuticals, JHP Pharmaceuticals, NitroMed, Ethicon, and Bristol-Myers Squibb, with a consistent focus on sales, commercial operations, and training. Chris holds a Bachelor of Arts from Rutgers University and a Master of Science from the University of Pennsylvania.